SRPT - Sarepta Therapeutics

-

$undefined

N/A

(N/A)

Sarepta Therapeutics NasdaqGS:SRPT Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Location: 215 First Street, Cambridge, MA, 02142, United States | Website: https://www.sarepta.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

4.628B

Cash

522.8M

Avg Qtr Burn

-136.8M

Short % of Float

9.40%

Insider Ownership

4.44%

Institutional Own.

90.37%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ELEVIDYS (SRP-9001) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

EXONDYS 51 (eteplirsen) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

ELEVIDYS (SRP-9001) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

Approved

Quarterly sales

VYONDYS 53 (golodirsen) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

SRP-9003 Details
Limb-Girdle Muscular Dystrophy (LGMD type 2E/R4)

Susp. Mover™

BLA

Submission

ELEVIDYS (SRP-9001) Details
Duchenne muscular dystrophy

Phase 3

Update

SRP-5051 (vesleteplirsen) Details
Duchenne muscular dystrophy

Phase 2

Update

SRP-9004 Details
Limb-Girdle Muscular Dystrophy (LGMD type 2D/R3)

Susp. Mover™

Phase 1

Data readout

SRP-6004 Details
Dysferlinopathy, Limb-Girdle Muscular Dystrophy

Phase 1

Update

SRP-9005 Details
Limb-Girdle Muscular Dystrophy (LGMD type 2C/R5)

Susp. Mover™

Phase 1

Initiation